NEW YORK--(BUSINESS WIRE)--Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of PharMerica Corporation (“PharMerica” or the “Company”) (NYSE: PMC) in connection with the proposed sale of the Company to Omnicare, Inc. (“Omnicare”) (NYSE: OCR) for approximately $441 million. On August 23, 2011, it was announced that Omnicare offered to buy PharMerica. PharMerica’s board of directors subsequently rejected the offer. Under Omnicare’s bid, PharMerica shareholders would have received $15.00 per share in cash. Our investigation concerns the board of directors’ process for consideration of the proposed transaction and whether the proposed consideration to be paid to PharMerica shareholders would be fair and adequate.
